Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197174 | 0.94 | MAPT (0.66) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL25575670 | 0.92 | MAPT (0.69) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL2835656 | 0.92 | MAPT (0.69) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL9860436 | 0.92 | MAPT (0.69) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| Iocanlidic Acid SCHEMBL290025 | 0.92 | MAPT (0.69) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL29256339 | 0.91 | MAPT (0.58) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL6208836 | 0.89 | SMN1; SMN2 (0.82) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL1007160 | 0.87 | FFAR1 (0.65) | FFAR1LMNAKEAP1 | |
| SCHEMBL69789 | 0.87 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| Iocanlidic Acid SCHEMBL27870026 | 0.86 | MAPT (0.61) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 796 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137821-A1 | PEPTIDE STRUCTURE TARGETING CARBONIC DEHYDROGENASE IX AND USE THEREOF | C-BIOMEX CO., LTD. (KR) | 2026-05-21 | — | — | US | claimed |
| US-12486304-B2 | Peptide ligand targeting carbonic anhydrase IX, peptide construct comprising same, and uses thereof | C-BIOMEX CO., LTD. (KR) | 2025-12-02 | — | — | US | claimed |
| EP-4652180-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Janssen Pharmaceutica NV (BE) | 2025-11-26 | — | — | EP | claimed |
| US-20250352498-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING PHENYLBUTYRATE AND METHODS THEREOF | AARDVARK THERAPEUTICS INC. (US) | 2025-11-20 | — | — | US | claimed |
| US-20250302981-A1 | NOVEL USE OF ANTICANCER AGENT PRODRUG CONJUGATE | UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION (KR) | 2025-10-02 | — | — | US | claimed |
| EP-4619043-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | Perspective Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250222143-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-07-10 | — | — | US | claimed |
| WO-2025128149-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | VIEWPOINT MOLECULAR TARGETING, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| US-20250186630-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | VIEWPOINT MOLECULAR TARGETING, INC. (US) | 2025-06-12 | — | — | US | claimed |
| CN-120118155-A | PD-L1 targeted polypeptide positron probe and preparation method and application thereof | 南方医科大学南方医院 | 2025-06-10 | — | — | CN | claimed |
| US-5843994-A | Compositions and methods for treating and preventing pathologies including cancer | THE UNITED STATES OF AMERICA AS REPRESENETED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-12-01 | — | — | US | claimed |
| US-5712307-A | Methods of inducing the production of hemoglobin and treating pathologies associated with abnormal hemoglobin activity using phemylacetic acids and derivatives therof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-27 | — | — | US | claimed |
| US-5710178-A | ARYL- AND ARYLOXYALKANOIC ACIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-20 | — | — | US | claimed |
| US-5708025-A | BY INDUCING PRODUCTION OF FETAL HEMOGLOBINS BY ADMINISTERING SPECIFIED ARYL ACIDS, DERIVATIVES, SALTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-13 | — | — | US | claimed |
| US-5708171-A | HISTAMINE H3-RECEPTOR ANTAGONIST | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-01-13 | — | — | US | claimed |
| US-5661179-A | ADMINISTERING; TREATS NEUROBLASTOMA, MYELODYSPLASIA, NON-SMALL CELL LUNG CANCER, PROSTATE CANCER, MELANOMA, BRAIN TUMOR, KAPOSI'S SARCOMA, LYMPHOMA, LEUKEMIA, BREAST AND LUNG CANCER, OSTEOSARCOMA AND FIBROSARCOMA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-26 | — | — | US | claimed |
| US-5654333-A | THERAPY FOR ANEMIA, CANCER, AIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-05 | — | — | US | claimed |
| US-5635533-A | ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | claimed |
| US-5635532-A | ADMINISTERING PHENYL OR NAPHTHYL ACETIC ACID DERIVATIVES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | claimed |
| US-5605930-A | ADMINISTERING PHENYLACETIC ACID AS AN INHIBITOR OF THE MEVALONATE PATHWAY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-02-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302981-A1 | NOVEL USE OF ANTICANCER AGENT PRODRUG CONJUGATE | KRAS, TP53, NRAS | SMN1; SMN2 3629/4885HDAC3 2769/4885MAPK1 1442/4885 |
| US-20250352498-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING PHENYLBUTYRATE AND METHODS THEREOF | ABAT, CPT1B, GABBR1 | SMN1; SMN2 762/4885HDAC3 757/4885MAPK1 4494/4885 |
| US-20250222143-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | PAICS, RABGGTB, PARP1 | SMN1; SMN2 3520/4885HDAC3 1275/4885MAPK1 4343/4885 |
| US-12486304-B2 | Peptide ligand targeting carbonic anhydrase IX, peptide construct comprising same, and uses thereof | CA9, CA4, CA12 | SMN1; SMN2 4080/4885HDAC3 3911/4885MAPK1 3293/4885 |
| US-20250186630-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | FAP, FIBP, TPX2 | SMN1; SMN2 3640/4885HDAC3 4414/4885MAPK1 2142/4885 |
| US-20260137821-A1 | PEPTIDE STRUCTURE TARGETING CARBONIC DEHYDROGENASE IX AND USE THEREOF | CA5A, CA1, CA9 | SMN1; SMN2 3004/4885HDAC3 656/4885MAPK1 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.